EUCTR2012-001514-42-IT进行中（未招募）1 期
A Phase 1/2, Dose-escalation, Open-label Study of Nivolumab orNivolumab in Combination with Other Agents in Advanced HepatocellularCarcinoma Subjects with or without Chronic Viral Hepatitis - Anti-PD-1 HCC
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 620
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Subjects of 18 years or older (men and women) with histologically
- •confirmed advanced hepatocellular carcinoma, not eligible for surgical
- •and/or locoregional therapies; or progressive disease after surgical and
- •/or locoregional therapies
- •-Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to
- •-Dose Escalation Phase: Child-Pugh score of 7 points or less. Cohort 5:
- •Child-Pugh Class B (B7 to B8). For all other cohorts Child-Pugh score of 6
- •points or less
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 372
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 248
排除标准
- •-History of autoimmune disease
- •-Any prior or current clinically significant ascites
研究者
相似试验
进行中（未招募）
1 期
A Phase 1/ 2 Study of the Oral Form of MLN9708 with Melphalan and Prednisone for Patients with Newly Diagnosed Multiple Myelomaewly diagnosed multiple myelomaMedDRA version: 16.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2010-023772-71-CZMillennium Pharmaceuticals, Inc158
进行中（未招募）
1 期
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of MLN9708, a Next-Generation Proteasome Inhibitor, Administered in Combination with a Standard Care Regimen of Melphalan and Prednisone in Patients With Newly-Diagnosed Multiple Myeloma Requiring Systemic Treatment.Estudio de fase 1/2, de aumento de dosis, abierto, de la formulación oral de MLN9708, un inhibidor de proteosoma de nueva generación, administrado en combinación con un régimen habitual de melfalán y prednisona en pacientes con mieloma múltiple de nuevo diagnóstico que precisan tratamiento sistémico -mieloma múltiple de nuevo diagnósticoMedDRA version: 12.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2010-023772-71-ESMillennium Pharmaceuticals, Inc163
进行中（未招募）
不适用
A Phase 1/ 2 Study of the Oral Form of MLN9708 with Melphalan and Prednisone for Patients with Newly Diagnosed Multiple Myelomaewly diagnosed multiple myelomaMedDRA version: 14.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-023772-71-ITMILLENNIUM PHARMACEUTICALS, INC.163
进行中（未招募）
1 期
A Phase 1/ 2 Study of the Oral Form of MLN9708 with Melphalan and Prednisone for Patients with Newly Diagnosed Multiple MyelomaEUCTR2010-023772-71-GBMillennium Pharmaceuticals, Inc61
进行中（未招募）
1 期
A Study of TAK-676 as Single Agent and TAK-676 in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid TumorsSolid NeoplasmsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2022-000528-39-ATTakeda Development Center Americas, Inc. (TDC Americas)368